Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 6Phase 1 5Phase NA 2Phase 1/2 1

Status

Completed 19Recruiting 6Terminated 3Active not recruiting 3Unknown 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Myeloid 6Classical hematology 1

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 42Stomach Neoplasms 35Neoplasm Metastasis 32Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

Hydroxyurea 2ruxolitinib 1givinostat hydrochloride 1givinostat 1bomedemstat 1N(4)-oleylcytosine arabinoside 1Interferons 1Interferon-alpha 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Polycythemia Vera × Clear all
NCT07429266 2026-06-05

INTREPID

Ono Pharmaceutical Co., Ltd.

Phase 3 Recruiting
250 enrolled
Myeloid

Polycythemia Vera

NCT04116502 2026-04-28

MITHRIDATE

University of Birmingham

Phase 3 Recruiting
586 enrolled
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06093672 2026-03-25

GIV-IN-PV

Italfarmaco

Phase 3 Recruiting
220 enrolled
Myeloid

Polycythemia Vera

NCT05198960 2026-03-20

AVAJAK

University Hospital, Brest

Phase 3 Recruiting
1,308 enrolled
Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT04655092 2024-11-08

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

PharmaEssentia Japan K.K.

Phase 3 Recruiting
67 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡